ARVN News and Press, Arvinas Inc. From 11/06/19

NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of...

NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock...

Arvinas (NASDAQ: ARVN ): Q3 GAAP EPS of -$0.54 misses by $0.07 . More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

NEW HAVEN, Conn., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter of 2019 and provided a corporate upda...

Shares of Arvinas ( ARVN ) have risen by 29% since my introductory article in April explored their early-stage research and value proposition within the very intriguing targeted protein degradation space, an approach which could have several advantages over current therapies. I'm choosing ...

Last week was an exciting one for anyone with shares of Arvinas   (NASDAQ: ARVN)  or  Biogen (NASDAQ: BIIB) in their portfolio. Both soared more than 30% during the week ended Oct. 25, and investors who didn't have these rockets in their portfolio might feel they're missing ou...

Thinly traded Arvinas ( ARVN +13.2% ) is up on double normal volume, albeit on turnover of only 386K shares, on the heels of preliminary data from Phase 1 clinical trials evaluating the safety, tolerability and pharmacokinetics of candidates ARV-110 (metastatic castration-resistant prost...

-Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers -Conference call to be held at 8:30 AM ET today NEW HAVEN, Conn., Oct. 23, 2019 (GLOBE N...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks T...

Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 Trials Neuroscience Presentation to Include Data from Preclinical Tau and Alpha-Synuclein Programs NEW HAVEN, Conn., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc., (Nasdaq...